Savara (SVRA) Preferred Stock Liabilities (2014 - 2016)
Savara (SVRA) reported Preferred Stock Liabilities of $43.9 million for Q4 2016, up 2.04% year-over-year from $43.0 million in Q1 2016, and up 2.04% quarter-over-quarter from $43.0 million in Q4 2015.
Savara (SVRA) Preferred Stock Liabilities (2014 - 2016) Analysis & Trends
Savara (SVRA) has 3 years of Preferred Stock Liabilities data on file, last reported at $43.9 million in Q4 2016.
- Preferred Stock Liabilities for Q4 2016 came in at $43.9 million, up 2.04% year-over-year; the trailing twelve-month figure through Dec 2016 was $43.9 million (up 2.04% YoY), and the FY2016 annual result was $43.9 million, up 2.04% from the prior year.
- Preferred Stock Liabilities improved to $43.9 million in Q4 2016 per SVRA's latest filing, from $43.0 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $43.9 million in Q4 2016 and troughed at $20.3 million in Q4 2014.
- A 3-year average of $35.7 million and a median of $43.0 million in 2015 frame the typical range for Preferred Stock Liabilities.
- The sharpest annual moves came in 2015 and 2016: Preferred Stock Liabilities soared 112.05% in 2015, then gained 2.04% in 2016.
- A 3-year view of Preferred Stock Liabilities shows it stood at $20.3 million in 2014, then jumped by 112.05% to $43.0 million in 2015, then rose by 2.04% to $43.9 million in 2016.
- Business Quant data shows SVRA's Preferred Stock Liabilities at $43.9 million in Q4 2016, $43.0 million in Q4 2015, and $20.3 million in Q4 2014.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Savara | 1.39 Bn | 1.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 43.86 Mn |
| Dec 31, 2015 | 42.99 Mn |
| Dec 31, 2014 | 20.27 Mn |